Výsledky vyhledávání - Myron S. Czuczman

Upřesnit hledání
  1. 1
    Use of rituximab, the new FDA-approved antibody

    Use of rituximab, the new FDA-approved antibody Autor Gail A. Leget, Myron S. Czuczman

    Vydáno 1998
    Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  2. 2
    Acquired Resistance to Rituximab Is Associated with Chemotherapy Resistance Resulting from Decreased Bax and Bak Expression

    Acquired Resistance to Rituximab Is Associated with Chemotherapy Resistance Resulting from Decreased Bax and Bak Expression Autor Scott H. Olejniczak, Francisco J. Hernandez‐Ilizaliturri, James L. Clements, Myron S. Czuczman

    Vydáno 2008
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  3. 3
    Prolonged Clinical and Molecular Remission in Patients With Low-Grade or Follicular Non-Hodgkin's Lymphoma Treated With Rituximab Plus CHOP Chemotherapy: 9-Year Follow-Up

    Prolonged Clinical and Molecular Remission in Patients With Low-Grade or Follicular Non-Hodgkin's Lymphoma Treated With Rituximab Plus CHOP Chemotherapy: 9-Year Follow-Up Autor Myron S. Czuczman, Robin Weaver, Baha Alkuzweny, Judy Berlfein, Antonio J Grillo-López

    Vydáno 2004
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  4. 4
    Regulation of CD20 in Rituximab-Resistant Cell Lines and B-cell Non-Hodgkin Lymphoma

    Regulation of CD20 in Rituximab-Resistant Cell Lines and B-cell Non-Hodgkin Lymphoma Autor Ping‐Chiao Tsai, Francisco J. Hernandez‐Ilizaliturri, Naveen Bangia, Scott H. Olejniczak, Myron S. Czuczman

    Vydáno 2012
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  5. 5
    Targeting CD20+ Aggressive B-cell Non–Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells <i>In Vitro</i> and in NSG Mice

    Targeting CD20+ Aggressive B-cell Non–Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells <i>In Vitro</i> and in NSG Mice Autor Yaya Chu, Jessica Hochberg, Ashlin Yahr, Janet Ayello, Carmella van de Ven, Matthew J. Barth, Myron S. Czuczman, Mitchell S. Cairo

    Vydáno 2014
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  6. 6
    Immunomodulatory drugs stimulate natural killer‐cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti‐tumour activity of rituximab <i>in vivo</i>

    Immunomodulatory drugs stimulate natural killer‐cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti‐tumour activity of rituxima... Autor Nishitha Reddy, Francisco J. Hernandez‐Ilizaliturri, George Deeb, Mark S. Roth, Mary Vaughn, Joy Knight, Paul K. Wallace, Myron S. Czuczman

    Vydáno 2007
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  7. 7
    Treatment-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Patients Treated With Ibritumomab Tiuxetan Radioimmunotherapy

    Treatment-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Patients Treated With Ibritumomab Tiuxetan Radioimmunotherapy Autor Myron S. Czuczman, Christos Emmanouilides, Mohamed Darif, Thomas E. Witzig, Leo I. Gordon, Stephen Revell, Katie D. Vo, Arturo Molina

    Vydáno 2007
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  8. 8
    Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20+ rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia

    Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20+ rituximab-sensitive/-re... Autor Aradhana Awasthi, Janet Ayello, Carmella van de Ven, Mona Elmacken, Anthony Sabulski, Matthew J. Barth, Myron S. Czuczman, Humayun Islam, Christian Klein, Mitchell S. Cairo

    Vydáno 2015
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  9. 9
    Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody

    Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody Autor David M. Goldenberg, Edmund A. Rossi, Rhona Stein, Thomas M. Cardillo, Myron S. Czuczman, Francisco J. Hernandez‐Ilizaliturri, Hans J. Hansen, Chien‐Hsing Chang

    Vydáno 2008
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  10. 10
    Entinostat, a novel histone deacetylase inhibitor is active in B‐cell lymphoma and enhances the anti‐tumour activity of rituximab and chemotherapy agents

    Entinostat, a novel histone deacetylase inhibitor is active in B‐cell lymphoma and enhances the anti‐tumour activity of rituximab and chemotherapy agents Autor Sarah Frys, Zachary Simons, Qiang Hu, Matthew J. Barth, Juan Gu, Cory Mavis, Joseph J. Skitzki, Song Liu, Myron S. Czuczman, Francisco J. Hernandez‐Ilizaliturri

    Vydáno 2015
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  11. 11
    Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development

    Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development Autor Juan Gu, Anil Singh, Kai Xue, Cory Mavis, Matthew J. Barth, Vivek Yanamadala, Peter Lenz, Michael Grau, Georg Lenz, Myron S. Czuczman, Francisco J. Hernandez‐Ilizaliturri

    Vydáno 2017
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  12. 12
    Chemoimmunotherapy with ofatumumab in combination with <scp>CHOP</scp> in previously untreated follicular lymphoma

    Chemoimmunotherapy with ofatumumab in combination with <scp>CHOP</scp> in previously untreated follicular lymphoma Autor Myron S. Czuczman, Georg Heß, Ole Gadeberg, Lars Møller Pedersen, Nancy Goldstein, Ira Gupta, Roxanne C. Jewell, Thomas S. Lin, Steen Lisby, Claus Strange, Kristian Windfeld, Andreas Viardot

    Vydáno 2012
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  13. 13
    Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma

    Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma Autor Kieron Dunleavy, Stefania Pittaluga, Myron S. Czuczman, Sandeep S. Davé, George W. Wright, Nicole Grant, Margaret Shovlin, Elaine S. Jaffe, John E. Janik, Louis M. Staudt, Wyndham H. Wilson

    Vydáno 2009
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  14. 14
    Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance)

    Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance) Autor John P. Leonard, Sin‐Ho Jung, Jeffrey L. Johnson, Brandelyn N. Pitcher, Nancy L. Bartlett, Kristie A. Blum, Myron S. Czuczman, Jeffrey K. Giguere, Bruce D. Cheson

    Vydáno 2015
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  15. 15
    Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response

    Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response Autor Asher Chanan‐Khan, Kena C. Miller, David Lawrence, Swaminathan P. Iyer, Austin Miller, Francisco Hernandez‐Illatazurri, Myron S. Czuczman, Paul K. Wallace, Jerome B. Zeldis, Kelvin H. Lee

    Vydáno 2010
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  16. 16
    Comparison of Referring and Final Pathology for Patients With Non-Hodgkin's Lymphoma in the National Comprehensive Cancer Network

    Comparison of Referring and Final Pathology for Patients With Non-Hodgkin's Lymphoma in the National Comprehensive Cancer Network Autor Ann S. LaCasce, Michelle E. Kho, Jonathan W. Friedberg, Joyce C. Niland, Gregory A. Abel, Maria Alma Rodriguez, Myron S. Czuczman, Michael Millenson, Andrew D. Zelenetz, Jane C. Weeks

    Vydáno 2008
    Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  17. 17
    Bendamustine is effective therapy in patients with rituximab‐refractory, indolent B‐cell non‐Hodgkin lymphoma

    Bendamustine is effective therapy in patients with rituximab‐refractory, indolent B‐cell non‐Hodgkin lymphoma Autor Brad S. Kahl, Nancy L. Bartlett, John P. Leonard, Ling Chen, Kristen N. Ganjoo, Michael E. Williams, Myron S. Czuczman, Katherine Robinson, Robin Joyce, Richard H. van der Jagt, Bruce D. Cheson

    Vydáno 2009
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  18. 18
    Biological effects and clinical significance of lenalidomide‐induced tumour flare reaction in patients with chronic lymphocytic leukaemia: <i>in vivo</i> evidence of immune activation and antitumour response

    Biological effects and clinical significance of lenalidomide‐induced tumour flare reaction in patients with chronic lymphocytic leukaemia: <i>in vivo</i> evidence of immune activat... Autor Asher Chanan‐Khan, Kasyapa S. Chitta, Noreen Ersing, Aneel Paulus, Aisha Masood, Taimur Sher, Abhisek Swaika, Paul K. Wallace, Terry Mashtare, Greg Wilding, Kelvin H. Lee, Myron S. Czuczman, Ivan Borrello, Naveen Bangia

    Vydáno 2011
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:
  19. 19
    The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Diffuse Large B Cell Lymphoma: Update of the 2001 Evidence-Based Review

    The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Diffuse Large B Cell Lymphoma: Update of the 2001 Evidence-Based Review Autor Denise M Oliansky, Myron S. Czuczman, Richard I. Fisher, Frank D. Irwin, Hillard M. Lazarus, James Omel, Julie M. Vose, Steven N. Wolff, Roy B. Jones, Philip L. McCarthy, Theresa Hahn

    Vydáno 2010
    Získat plný text Získat plný text
    Revisão
    Přidat do oblíbených
    Uloženo v:
  20. 20
    CALGB 150905 (Alliance): Rituximab Broadens the Antilymphoma Response by Activating Unlicensed NK Cells

    CALGB 150905 (Alliance): Rituximab Broadens the Antilymphoma Response by Activating Unlicensed NK Cells Autor Juan Du, Sandra López‐Vergès, Brandelyn N. Pitcher, Jeffrey L. Johnson, Sin‐Ho Jung, Lili Zhou, Katharine C. Hsu, Myron S. Czuczman, Bruce D. Cheson, Lawrence Kaplan, Lewis L. Lanier, Jeffrey M. Venstrom

    Vydáno 2014
    Získat plný text Získat plný text
    Artigo
    Přidat do oblíbených
    Uloženo v:

Vyhledávací nástroje: